Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04586543
Other study ID # MAO201901
Secondary ID 2019-002685-12
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 18, 2020
Est. completion date February 1, 2025

Study information

Verified date October 2020
Source University of Pecs
Contact László Mangel, Prof. MD
Phone +36-72-536-480
Email mangel.laszlo@pte.hu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this clinical study is to evaluate the effectiveness and safety of selegiline plus docetaxel therapy compared to the standard of care - docetaxel therapy - among patients diagnosed with metastatic, castrate-resistant prostate adenocarcinoma.


Description:

Prostate cancer is one of the leading cause of cancer death among males worldwide. The objective of this phase II, randomized, controlled, open label study is to evaluate the effectiveness and safety of MAO-B (Monoamine oxidases-B) inhibitor selegiline plus docetaxel therapy. Patients diagnosed with metastatic, castrate-resistant prostate adenocarcinoma are randomly divided into two groups. One group (control arm) receives docetaxel (75 mg/m2 IV every 3 weeks for maximum of 12 cycles). Another group (experimental arm) receives docetaxel (75 mg/m2 IV every 3 weeks for maximum of 12 cycles) plus selegiline (daily 10 mg tablet). Patients are followed up for 36 months or until the end of the trial, death or withdraw from this study due to other reasons. The primary endpoint of this study is the proportion of patients without progression at month 9. The secondary endpoint is proportion of patients without progression at month 12/18, progression-free survival, overall survival, duration of PSA response, radiological response rate, PSA response rate, health-related quality of life and safety.


Recruitment information / eligibility

Status Recruiting
Enrollment 110
Est. completion date February 1, 2025
Est. primary completion date February 1, 2025
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age 18 years or older male patients,

2. Histologically or cytologically confirmed prostate adenocarcinoma

3. Radiologically confirmed metastatic disease,

4. Eligibility to receive oral therapy,

5. Suitable for docetaxel therapy,

6. Patients with castration-resistant prostate carcinoma who eligible to first-line docetaxel therapy or patients with castration-resistant prostate cancer who progressed after second-generation hormone therapy (abiraterone or enzalutamide) with pre-chemotherapy indication and eligible to second-line docetaxel therapy

7. At least 4 weeks has elapsed between the last antiandrogenic therapy and the inclusion (at least 6 weeks in case of bicalutamide),

8. Planned docetaxel treatment,

9. Eastern Cooperative Oncology Group (ECOG) performance status: = 2,

10. Estimated life expectancy of more than 12 weeks,

11. Adequate analgesic therapy as required;

12. Patients must be able to follow the diet and medical instructions,

13. Use of effective contraception in men of childbearing age,

14. Provision of signed, written information consent

Exclusion Criteria:

1. De novo metastatic patients who needs immediate docetaxel therapy;

2. Within 4 weeks prior to randomisation, the patient has received other study medication or failed to recover from any adverse events caused from a previously administered study drug

3. = Grade 2 anticancer therapy-related toxicity (except alopecia),

4. Has had radiotherapy or immunotherapy within 4 weeks prior to treatment,

5. Has had a surgery within 4 weeks prior to treatment,

6. Known or suspected brain metastasis (stable patients with locally treated, asymptomatic brain metastases are not excluded),

7. Inadequate laboratory function:

1. Absolute neutrophil count <1.5 x 109 /L (1,500 per mm3),

2. Platelet count < 100 x 109 /L (100 000 per mm3),

3. Hemoglobin =9.0 g/dL,

4. Serum bilirubin > ULN,

5. AST or ALT

i.>2.5 x ULN in patient without liver metastases, ii.>5x ULN in patients with liver metastases.

8. Cardiological status:

1. Uncontrolled hypertension (BP = 150/95 with hypertension treatment)

2. Heart failure (NYHA III or higher),

3. Current or former diagnosis of cardiomyopathy,

4. LVEF = 50%,

5. Atrial fibrillation with >100bpm pulse,

6. Unstable ischemic heart disease (myocardial infarction within 6 months or angina that require more than one nitrate therapy each week).

9. Other uncontrolled or severe systemic disease, active infection, hepatitis B, hepatitis C, HIV,

10. Uncontrolled seizure disorder,

11. Active gastric and duodenal ulcers,

12. Recurrent nausea and vomiting, chronic gastrointestinal disease or intestinal resection that prevents proper absorption,

13. Severe psychiatric illness (including but not limited to manic psychiatric disorder, schizophrenia, bipolar disorder, major depression requiring hospitalization) or social disturbance that limits eligibility for examination,

14. History of other malignancy within the last 5 years (except properly treated basalioma or squamous cell carcinoma of the skin and in situ carcinoma),

15. History of allergic reaction to phenelzine, selegiline or other monoamine oxidase inhibitors (MAOIs) biological agents or similar chemical ingredients,

16. History of allergic reaction to docetaxel therapy or its ingredients,

17. Significant peripheral neuropathy (= Grade 2),

18. Selegiline is contra-indicated for concomitant use with:

1. Certain narcotic analgesics (eg. pethidine),

2. Drugs that enhance the sympathetic nervous system,

3. Other MAO inhibitors,

4. Drugs similar to MAO inhibitors,

5. Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs),

6. Tricyclic antidepressants.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Selegiline
10 mg selegiline tablet per day
Docetaxel
75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles

Locations

Country Name City State
Hungary University of Pécs, Clinical Centre, Department of Oncotherapy Pécs Baranya

Sponsors (2)

Lead Sponsor Collaborator
László Mangel E-Group ICT Software Informatikai Zrt.

Country where clinical trial is conducted

Hungary, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients without progression at month 9 Proportion of patients without progression at month 9. Progression can be identified by clinical symptoms, PSA levels, or radiographic imaging as follows, based on PCWG2 criteria:
Progression based on clinical symptoms:
Decline in ECOG performance status (= grade 3),
Initiation of newly adjusted chronic opioid analgesic therapy, which may be,
i.Use of oral opioid for at least 3 weeks ii.Use of parenteral opioid for at least 7 days c.Necessity to initiate alternative cytotoxic chemotherapy or other active systemic oncology treatment d.Immediate need for radiation or surgical intervention to treat tumor progression OR
PSA progression: Date at which the PSA level is increased by at least 25% relative to nadir and at least 2 ng / mL absolute increase compared to the nadir. Values are confirmed 4-6 weeks later by a test.
OR
Radiological
Progression by RECIST 1.1.
Bone scan progression: A total of = 2 new lesion compared to baseline
12 months
Secondary Proportion of patients without progression at month 12 15 months
Secondary Proportion of patients without progression at month 18 21 months
Secondary Progression-free survival (biochemical, clinical, radiological 5 years
Secondary Overall survival 5 years
Secondary Duration of PSA response 5 years
Secondary Radiological Response Rate 5 years
Secondary PSA Response Rate 5 years
Secondary Health-Related Quality of Life 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT04986423 - ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT05489991 - A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Phase 1/Phase 2
Active, not recruiting NCT05521412 - EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T Phase 1/Phase 2
Terminated NCT04556617 - PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 1/Phase 2
Completed NCT02125357 - Sequencing Abiraterone and Enzalutamide in mCRPC Phase 2
Recruiting NCT06052306 - A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) Phase 1
Recruiting NCT05917470 - A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. Phase 1/Phase 2
Recruiting NCT05519449 - Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) Phase 1
Terminated NCT05301062 - A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
Recruiting NCT05383079 - Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer Phase 1/Phase 2
Active, not recruiting NCT04060394 - Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC Phase 1/Phase 2
Completed NCT01942837 - Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer Phase 2
Recruiting NCT05458544 - [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application Phase 1/Phase 2
Withdrawn NCT04879589 - Phase 1 Study of ATRS-2002 in Healthy Male Adults Phase 1
Recruiting NCT03230734 - Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer Phase 2
Recruiting NCT05116579 - Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
Active, not recruiting NCT03732820 - Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer Phase 3
Recruiting NCT05005728 - XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05762536 - Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC Phase 2